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Abstract
Background: Coffee, a source of antioxidants, has controversial effects on cardiovascular health.
Objective:We evaluated the bioavailability of chlorogenic acids (CGAs) in 2 coffees and the effects of their consumption
on the plasma antioxidant capacity (AC), the serum lipid profile, and the vascular function in healthy adults.
Methods: Thirty-eight men and 37 women with a mean 6 SD age of 38.5 6 9 y and body mass index of 24.1 6 2.6 kg/m2
were randomly assigned to 3 groups: a control group that did not consume coffee or a placebo and 2 groups that consumed
400 mL coffee/d for 8 wk containing a medium (MCCGA; 420 mg) or high (HCCGA; 780 mg) CGA content. Both were low in
diterpenes (0.83mg/d) and caffeine (193mg/d). Plasma caffeic and ferulic acid concentrationsweremeasured byGC, and the
plasma ACwas evaluated with use of the ferric-reducing antioxidant power method. The serum lipid profile, nitric oxide (NO)
plasma metabolites, vascular endothelial function (flow-mediated dilation; FMD), and blood pressure (BP) were evaluated.
Results: After coffee consumption (1 h and 8 wk), caffeic and ferulic acid concentrations increased in the coffee-drinking
groups, although the values of the 2 groups were significantly different (P < 0.001); caffeic and ferulic acid concentrations
were undetectable in the control group. At 1 h after consumption, the plasma AC in the control group was significantly
lower than the baseline value (22%) and significantly increased in the MCCGA (6%) and HCCGA (5%) groups (P < 0.05).
After 8wk, no significant differences in the lipid, FMD, BP, or NO plasmametabolite valueswere observed between the groups.
Conclusions: Both coffees, which contained CGAs and were low in diterpenes and caffeine, provided bioavailable CGAs
and had a positive acute effect on the plasma AC in healthy adults and no effect on blood lipids or vascular function. The
group that did not drink coffee showed no improvement in serum lipid profile, FMD, BP, or NO plasma metabolites. This
trial was registered at registroclinico.sld.cu as RPCEC00000168. J Nutr 2016;146:524–31.
Keywords: cardiovascular disease, chlorogenic acids, phenolic acids, oxidative stress, diterpenes, caffeine,
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Introduction
Coffee has been recognized as a natural source of antioxidants
because of its phenolic compound content, of which chlorogenic
acids (CGAs)9 are the most prevalent (1). These compounds may
play a key role in inhibiting LDL cholesterol lipid peroxidation
and in modulating oxidative stress, thereby lowering the risk of
atherosclerosis (2). After CGAs are acutely consumed, they
appear not to be absorbed as such. Instead, CGAs have been
shown to be hydrolyzed in the gastrointestinal tract, which
results in the generation of end products such as caffeic and
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ferulic acids (3). In vitro studies have shown that the antioxidant
capacity (AC) of coffee is high and comparable to that of red
wine and green tea (4).
An imbalance of antioxidant defenses and the production
of reactive oxygen species have been identified as one of the
mechanisms underlying the development of cardiovascular
diseases (CVDs). Reactive oxygen species generate oxidative
stress and contribute to endothelial dysfunction, an event that
has also been identified as a risk factor for CVD (5).
The effect of coffee consumption on lipid profiles and
vascular function is unclear. Coffee intake has been associated
with an increase in total cholesterol (TC) (6), which was
attributed to the diterpene compounds (cafestol and kahweol)
that are present in boiled coffee. These compounds are extracted
because of the high temperatures and prolonged extraction time
of this type of coffee preparation (7). Some studies have shown
that the use of filters during the preparation of coffee could
reduce the amount of diterpenes and the effect on TC (8, 9). In a
study by Ahola et al. (8) that used a crossover design, 20 healthy
volunteers randomly consumed strong boiled coffee or filtered
boiled coffee for 4 wk; an increase in TC was observed only
in the group that consumed unfiltered coffee. In a review,
Rodrigues et al. (9) summarized the most relevant results
regarding the effect of coffee consumption on various risk
factors for CVD, lipid profiles, and other measures and also
found a positive association between unfiltered coffee consump-
tion and increased TC. Contrary to these reports, other studies
have reported increased TC when subjects consumed filtered
coffee (10, 11). In a parallel clinical trial of 120 nonsmoking
healthy subjects, Strandhagen et al. (10) showed that consuming
600 mL filtered coffee/d for 4 wk significantly increased TC
and that not consuming coffee significantly reduced TC. The
available studies have limitations related to small sample sizes,
the inclusion of only men or few women, and underrepresen-
tation of specific age or ethnic groups. In addition, the amount of
coffee consumed by the participants was difficult to determine in
some of the studies, whereas others did not report either the
coffee cup size or the coffees chemical characteristics.
The reported relations between coffee consumption and
endothelial function are contradictory. Some studies that
evaluated the effect of the consumption of coffee with caffeine
concentrations between 80 and 130 mg by healthy adults have
reported a decrease in flow-mediated dilation (FMD) (12, 13);
contrary to the studies cited previously, another study showed
that in both healthy individuals and those with coronary
arterial disease, FMD increased 1 h after the intake of 200 mg
of pure caffeine (14). In contrast, Mubarak et al. (15) did not
find any effect on FMD after the consumption of 400 mg of
pure CGAs, which is equivalent to the amount found in 2 cups
of coffee.
Within the past few years, epidemiological studies have
associated coffee consumption with a low risk of CVD.
Freedman et al. (16) explored the associations between coffee
consumption and subsequent total and cause-specific mortality
among 229,119 men and 173,141 women in the NIH-AARP
diet and health study; these participants were aged 50–71 y at
the start of the study. The results showed a significant inverse
association between coffee consumption and death from all
causes and specifically with death resulting from heart disease.
Because coffee is among the most widely consumed beverages in
the world, it is important to explore its antioxidants and their
effects on cardiovascular health. This study evaluated the
bioavailability of the chlorogenic and phenolic acids provided
by 2 types of filtered coffee with different CGA contents, which
was measured based on 2 major CGA metabolites (caffeic and
ferulic acids). The effects of the CGAs on the plasma AC, lipid
profiles, and vascular function in healthy adults were then
evaluated.
Methods
Study design. The controlled clinical trial was single-blinded with
respect to the analysis. The participants, who were apparently healthy
adult volunteers who were habitual coffee drinkers and who met the
inclusion criteria, were randomly assigned to 3 study groups: a control
group (no coffee consumption, no placebo) and 2 groups that drank 1 of
2 types of coffee (400 mL/d) for 8 wk that differed with respect to CGA
content. The sample size was calculated based on the reported minimum
mean difference of plasma AC with use of ferric-reducing antioxidant
power (FRAP) [22 6 12 mmol Fe2+/L (17)] and on changes in LDL
cholesterol concentration [17.1 6 18.8-mg/dL difference between a
treated group (coffee consumption) and the control group (no coffee
consumption, no placebo) (GM Agudelo-Ochoa, unpublished results,
2008)]. For a power of 0.8 and a significance level of 0.05, 25 subjects
were selected per group for a total of 75 (Figure 1).
Subjects. The volunteer subjects consisted of 38 men and 37 women
who met the following inclusion criteria: aged 20–60 y; BMI (in kg/m2)
between 18.5 and 29.9; regular coffee drinker (at least 3 cups/d; 1 cup =
;100 mL); nonsmoker; physical activity of <10 h/wk; no history and/or
diagnosis of chronic disease (cardiovascular, gastric, or psychiatric
disorder; dyslipidemia; diabetes; cancer; renal or liver alteration; hypo-
thyroidism; insomnia; dysautonomia; or sleep disturbance); not currently
consuming medication (lipid-lowering drugs, antioxidant dietary sup-
plements, anticonvulsants, anti-inflammatory steroids, hypnotics, or
FIGURE 1 Study design. CGA, chlorogenic acid; HCCGA, high
chlorogenic acid content; MCCGA, medium chlorogenic acid content.
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caffeine); and a maximum alcohol consumption of 10 units/wk for
women and 15 units/wk for men (1 unit = 10 g of ethanol). Pregnant
or nursing women, highly competitive athletes, and vegetarians
were excluded. The study was approved by the CES University Ethics
Committee and registered with the International Clinical Trials
Registry Platform (RPCEC00000168).
The volunteers provided informed consent and were randomly
assigned to 3 groups (matched for age, sex, and BMI): the control group
and the 2 groups in which the participants drank 400 mL coffee/d with
1 of 2 CGA contents: a mediumCGA content (MCCGA; 420mg) or high
CGA content (HCCGA; 780 mg). Both coffees were low in the
diterpenes kahweol (MCCGA: 0.89 mg/d; HCCGA: 0.92 mg/d) and
cafestol (0.75 mg/d) and in caffeine (MCCGA: 188 mg/d; HCCGA:
197 mg/d). The total CGAs and phenolic acid content was defined as the
sum of the individual contributing acids: 5-O-caffeoylquinic; 3-O-
caffeoylquinic; 4-O-caffeoylquinic; caffeic; ferulic; 3,4-di-O-caffeoyl-
quinic; 3,5-di-O-caffeoylquinic; and 4,5-di-O-caffeoylquinic. This content
was known by the researchers after the results were analyzed.
The week before the beginning of the study (washout period) and
during the 8 wk of the intervention, all participants avoided consuming
beverages with caffeine as well as beverages or foods that were naturally
high in antioxidants (tea, dark chocolate, red wine, cocoa-derived
products, herb infusions, berries, and soy) or that were enriched with
antioxidants. They also avoided any antioxidant supplements, and the
consumption of caffeine-containing drugs was forbidden. The partici-
pants were allowed to consume water, juices, milk, and other beverages
without caffeine. Except for these restrictions, the volunteers continued
their usual diets and lifestyles during the intervention. All of the
volunteers received advice and support during the intervention to resolve
any questions. During the intervention, the coffee drink was prepared
and provided in the workplace; the volunteers were trained to prepare
the drink as needed on weekends and received the necessary materials
(coffee maker, filters, cups, and ground coffee). The research team
monitored the participants for possible withdrawal symptoms and
provided general recommendations for managing such symptoms. At the
beginning and end of the intervention, the participants answered a
semiquantitative survey on their consumption of antioxidant-containing
foods aside from coffee; a change of 10% was permitted between the
baseline and postintervention surveys.
Coffee beverage preparation and chemical characterization.
Colombian Arabica coffee that was prepared by Colcafe´ S.A.S. was used.
Until it was prepared, the coffee was stored in laminated packaging with
a nitrogen-modified atmosphere. The coffee beverage was prepared
by using the paper-filtered drip method (6 g/100 mL water). Standard
HPLC procedures were used to chemically characterize the CGAs and to
determine the caffeine content [CGAs: (18); caffeine: (19)]. Cafestol and
kahweol were quantified according to Silvia et al. (20).
Anthropometric assessment. Each participants weight, height, and
waist circumference were measured at the beginning and end of the inter-
vention after the evaluators were standardized by using internationally
accepted equipment and techniques (21). BMIs and waist circumferences
were calculated and classified according to WHO criteria (22).
Biochemical tests. Blood samples were drawn by puncturing the
antecubital vein to obtain serum and plasma. For each participant, the
plasma concentration of caffeic and ferulic acids, AC, lipid profile, and
NO plasma metabolites were evaluated at baseline and 8 wk after
coffee consumption (chronic time point). In the 3 groups, the plasma
concentration of caffeic and ferulic acids and the AC were evaluated
1 h after the assigned intervention (acute time point). In the control
group, the serum caffeine levels were evaluated with GC/MS at
baseline and at weeks 4 and 8 (23). The plasma measurements at 8 wk
were performed on samples that were taken 21 h after the last coffee
consumption.
Quantification of plasma concentrations of caffeic and ferulic
acid. Plasma was obtained by centrifugation at 1200 3 g for 15 min at
4Cwith use of 0.109 mol/L sodium citrate as an anticoagulant and then
stored at280C until analysis. Enzymatic digestion was performed with
glucuronidase and sulfatase (24); subsequent cleaning was performed via
extraction in the solid phase. The obtained substances were derivatized
with N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide with 1% tert-
butyldimethylchlorosilane and then analyzed by GC. Detection was
performed with a quadrupole mass spectrometer. The reproducibility of
the analytical system was determined (relative SD of 1.2% and 1.4% for
the caffeic acid and ferulic acid, respectively). The recovery rate for this
method was 97.58% for ferulic acid and 97.27% for caffeic acid; the
analytical method was exact, and the concentration factor did not affect
the variability of the results obtained. The limit of detection (LOD) and
quantification was determined based on the SD of the response at low
concentrations. The LODwas expressed based on the replicates of a low
concentration that produced a signal-to-noise ratio >6:1 and a relative
SD <20%. The LODwas 3 nM for caffeic acid and 5 nM for ferulic acid.
The quantification was performed by using the external standard method.
Plasma antioxidant capacity. The FRAP method was applied to
plasma samples immediately after they were obtained according to the
method of Benzie and Szeto (25) with slight modifications. Briefly, the
FRAP reaction (300 mM FRAP reagent, 40 mM ferric-tripyridyltriazine/
HCl, and 20 mMFeCl3.6H2O) was monitored in a microwell plate assay
TABLE 1 Characteristics of the healthy adults assigned to the three study groups1
Study group, n (%)
Total P2Control (n = 25) MCCGA (n = 25) HCCGA (n = 24)
Gender 0.91
Men 13 (52) 12 (48) 12 (50) 37
Women 12 (48) 13 (52) 12 (50) 37
Age, y 0.51
20–40 14 (56) 14 (56) 10 (42) 38
41–60 11 (44) 11 (44) 14 (58) 36
BMI,3 kg/m2 0.92
Normal 16 (64) 15 (60) 14 (58) 45
Overweight 9 (36) 10 (40) 10 (42) 29
Waist circumference,4 cm 0.39
Adequate 24 (96) 24 (96) 21 (88) 69
High 1 (4) 1 (4) 3 (12) 5
1 HCCGA, high chlorogenic acid content; MCCGA, medium chlorogenic acid content.
2 Chi-square test.
3 Normal BMI: 18.5–24.9; overweight: 25–29.9.
4 Appropriate waist circumference: men: #94 cm; women: #80 cm.
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instead of cuvettes, and the Trolox calibration solutions (31.25–1000 mM)
were prepared in PBS. The analyses were performed in triplicate, and the
results were expressed inmicromolar equivalent Trolox per liter of plasma.
Lipid profile. Plasma containing lithium heparin, which was obtained
by centrifuging blood samples at 1200 3 g for 15 min at 4C, was used.
Plasma TC, HDL cholesterol, and TGs were enzymatically measured
with use of cholesterol oxidase/peroxidase, cholesterol HDL direct, and
TG glycerol phosphate oxidase/peroxidase commercial kits (BioSystems
S.A.).The LDL cholesterol values were obtained by calculation (26).
Vascular function. Vascular function was assessed according to the
following parameters:
d FMD of the brachial artery: In accordance with Breto´n et al. (27),
this measurement was performed in a temperature-controlled room
(22C) while the participants were fasting. A 7.5–13-MHz linear
transducer connected to ultrasound equipment with a vascular
program (General Electric Logic P5 and Toshiba Nemio XG) was
used. To ensure the accuracy and reproducibility of the data, each
volunteer was evaluated on the same equipment and by the same
evaluator, who was previously trained and standardized.
d Blood pressure (BP): BP was obtained according to the standard
techniques of the AHA and the European Cardiology Association.
The subjects rested between 3 and 5 min. The cutoff for normal BP
was 120/80 mm Hg (28).
d NO metabolites: These measurements were performed with a
nitrate/nitrite colorimetric kit that is commercially available from
Cayman Chemical Company. The quantification was performed
from calibration curves, and values were expressed in mmol/L of
plasma (29).
Statistical analysis. The age, sex, and BMI of the study population was
described with use of measures of central tendency and dispersion for
quantitative variables (data are expressed as the mean 6 SD), whereas
the qualitative variables were described through frequencies and
percentages. A chi-square test was used to establish the comparability of
independent variables between the study groups. The normality of the
continuous variables in each group was evaluated with the Shapiro-
Wilks test. To evaluate the differences in caffeic and ferulic acid
concentrations between the treated groups, the Mann-Whitney U test
was used. To evaluate the effect of the type of coffee consumed, a repeated-
measures ANOVA that took into account 2 time points (baseline and
8 wk) and the 3 treatments (control, MCCGA, and HCCGA) was
performed; to evaluate AC, 3 time points (basal, 1 h, and 8 wk) and the
3 treatments mentioned previously were taken into account. When an
interaction was significant, Tukeys post hoc tests were applied. The
normality assumptions of the model were checked, and transformations
were applied (log for TGs andHDL cholesterol and square root for NO) to
the data for variables that were not normally distributed. Systolic
blood pressure and diastolic blood pressure were not normally
distributed even after transformation and were therefore analyzed by
using the nonparametric Kruskal-Wallis test. Significance was defined
as P < 0.05, and 2-tailed tests were used. The statistical analysis was
performed by using SPSS version 22 (IBM).
Results
Of the 75 volunteers who began the study, 74 completed it;
1 individual in the group that consumed the HCCGA coffee was
excluded because of alterations in baseline lipids that required
medication. Table 1 shows the characteristics of the volunteers
in each group at baseline. Table 2 describes the characteristics of
the 2 coffees used.
At baseline, the concentrations of caffeic and ferulic acid
were below the detection threshold in all of the groups. The
same situation was observed in the control group after 8 wk of
intervention. Between the groups that drank coffee, the caffeic
and ferulic acid concentrations were significantly higher in the
MCCGAgroup at each of the 2measurement time points (Table 3).
A significant time 3 treatment interaction was found for the
plasma AC (P < 0.001). Repeated-measures ANOVA revealed
that the AC was significantly lower than the baseline value in the
control group at 1 h after coffee intake (P < 0.05). This result
differs from what was observed in the groups that drank coffee;
in these groups, the AC significantly increased (P < 0.05). At
8 wk, the AC decreased in the 3 groups, and the values did not
significantly differ (Table 4).
There was not a significant time 3 intervention interaction
effect for the lipid profile, FMD, or NO plasma metabolites (P >
0.05) (Table 5). There were no significant differences (P > 0.05)
between pre- and posttreatment for systolic BP (control: 108 6
7/106 6 7; MCCGA: 108 6 9/109 6 11; HCCGA: 110 6 10/
109 6 8 mm Hg) and diastolic BP (control: 75 6 8/75 6 5;
MCCGA: 74 6 7/75 6 7; HCCGA: 75 6 8 /76 6 6 mm Hg).
In the control group, no caffeine was detected in the plasma
at any of the 3 time points evaluated (baseline and weeks 4 and
8), confirming adherence to the intervention. No significant
changes were found in the semiquantitative survey of the
frequency of consumption of foods of interest between the
beginning and end of the intervention.
Discussion
The results of various studies over the last decade have demon-
strated the antioxidant effect of the CGAs provided by coffee.
However, it has been suggested that the absorption of CGAs
might be low because of their esterification (30). Several studies
have concluded that CGAs in coffee are bioavailable (31, 32).
Renouf et al. (24) provided healthy volunteers with a single dose
TABLE 3 Plasma caffeic and ferulic acid concentrations at
baseline and at 1 h and 8 wk after the intervention in healthy
adults1
Control (n = 25) MCCGA (n = 25) HCCGA (n = 24)
Caffeic acid, nM
Baseline ND ND ND
1 h ND 50.5 6 6.9a 20.3 6 3.3b
8 wk ND 14.1 6 0.8a 9.0 6 1.5b
Ferulic acid, nM
Baseline ND ND ND
1 h ND 201 6 18.7a 137 6 6.1b
8 wk ND 44.6 6 0.6a 34.3 6 2.1b
1 Values are means 6 SDs. The 8-wk sample was obtained 21 h after the last
consumption. Labeled means within a row without a common letter differ significantly
(Mann-Whitney U test; P , 0.001). HCCGA, high chlorogenic acid content; MCCGA,
medium chlorogenic acid content; ND, not detected (caffeic acid ,3 nM and ferulic
acid ,5 nM).
TABLE 2 Characteristics of the 2 types of coffee used in the
study1
Components
Medium CGA coffee High CGA coffee
mg/100 mL2 mg/400 mL mg/100 mL2 mg/400 mL
Caffeine 47 6 1.4 188 49 6 1 197
Total CGAs 105 6 4.1 420 195 6 6.9 780
Diterpenes
Cafestol 0.19 6 0.03 0.75 0.19 6 0.01 0.75
Kahweol 0.22 6 0.03 0.89 0.23 6 0.02 0.92
1 CGA, chlorogenic acid.
2 Values are means 6 SDs.
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of 335 mg of soluble CGAs in coffee and showed the presence of
2 groups of metabolites, the maximum concentrations of which
were achieved between 1–12 h after coffee consumption. In our
study, caffeic and ferulic acids were present in the groups that
drank coffee and were not detectable in the control group, both
after 1 h as well as 8 wk after the start of the intervention. These
findings are consistent with previous results. It is important to
note that at both the acute and chronic time points the 2
metabolites were present at significantly higher concentrations
in the group assigned to drink the MCCGA coffee. Similar
results were found in the study conducted by Stalmach et al.
(33), in which reduced absorption in the small intestine was
found to be associated with ingestion of the highest dose of some
metabolites, probably because of saturation of the absorption
sites.
Coffee is now recognized as a source of potent antioxidants,
principally CGAs, that could help improve the redox state of
plasma and prevent the oxidation of LDL (34). Natella et al. (35)
reported that in healthy volunteers, the AC was higher after the
consumption of coffee instead of tea; however, other studies of
healthy adults have not found any effects of coffee on plasma AC
(36). In our study, 1 h after the 2 types of coffee had been
consumed, the plasma AC of the volunteers was significantly
increased over the baseline value, in contrast to the plasma AC
of the participants in the control group, which declined over the
same period. Similar results were reported by Correˆa et al. (37),
who found an increase in the AC in subjects who had consumed
2 types of filtered coffee that were roasted to different degrees
and that had different CGA contents for 4 wk. An increase in
plasma AC provides greater protection against free radicals,
which helps reduce key events in the development of CVD. The
results of our study regarding the bioavailability of the CGAs in
coffee and their effects on the AC in healthy adults suggest an
acute positive effect that tends to decrease as the metabolites are
TABLE 4 Antioxidant capacity of plasma at baseline, 1 h, and 8 wk after the intervention in healthy
adults1
Control (n = 25) MCCGA (n = 25) HCCGA (n = 24)
P
Treatment Time Interaction
FRAP, μmol ET/L
Baseline 562 6 70.8 584 6 63.6 563 6 78.5 0.11 ,0.001 ,0.001
1 h 553 6 71.6*b 618 6 59.9*a 590 6 81.3*a,b
8 wk 519 6 80.3*a 552 6 59.3*a 533 6 71.0*a
1 Values are means 6 SDs. Labeled means in a row without a common letter differ significantly (repeated-measures ANOVA; P , 0.01).
*Differences within the same group relative to baseline (repeated-measures ANOVA; P , 0.05). ET, equivalent Trolox; FRAP, ferric-
reducing antioxidant power; HCCGA, high chlorogenic acid content; MCCGA, medium chlorogenic acid content.
TABLE 5 Markers of serum lipid profile and vascular function in healthy adults at baseline and 8 wk
after the intervention1
Control (n = 25) MCCGA (n = 25) HCCGA (n = 24)
P2
Treatment Time Interaction
Cholesterol, mg/dL
Baseline 196 6 32.7 196 6 33.4 211 6 31.0 0.26 0.02 0.69
8 wk 203 6 38.2 201 6 35.9 214 6 32.1
LDL cholesterol, mg/dL
Baseline 104 6 21.7 101 6 22.5 118 6 24.7 0.04 0.29 0.58
8 wk 107 6 26.0 103 6 23.8 118 6 23.2
HDL cholesterol, mg/dL
Baseline 50.7 6 13.9 52.9 6 12.8 50.6 6 10.3 0.84 0.16 0.26
8 wk 52.4 6 12.5 53.2 6 13.5 51.0 6 10.9
TGs, mg/dL
Baseline 114 6 53.6 118 6 56.0 121 6 51.7 0.74 0.09 0.37
8 wk 125 6 101.8 134 6 65.1 122 6 51.2
Arterial index
Baseline 4.1 6 1.0 3.9 6 0.9 4.3 6 0.9 0.33 0.42 0.53
8 wk 4.0 6 1.1 4.0 6 1.1 4.3 6 0.9
FMD, %
Baseline 13.2 6 11.1 13.6 6 12.3 21.3 6 11.0 0.26 0.13 0.50
8 wk 18.4 6 18.1 19.5 6 18.1 21.1 6 21.2
NO metabolites, μmol/L
Baseline 3.0 6 1.3 3.3 6 1.0 3.0 6 1.1 0.20 0.49 0.27
8 wk 2.7 6 1.7 4.0 6 3.6 4.3 6 3.5
1 Values are means 6 SDs. FMD, flow-mediated dilation; HCCGA, high chlorogenic acid content; MCCGA, medium chlorogenic acid
content.
2 Repeated-measures ANOVA.
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eliminated by the body. The fact that the plasma AC increased
1 h after the consumption of the 2 coffee beverages and signifi-
cantly increased after the consumption of the MCCGA coffee
suggests that other substances with antioxidant properties may
have been generated during the roasting process, which differed
for the 2 coffees. This result illustrates the need to characterize
this matrix in more detail so that other substances and the
synergy between them can be identified.
An important finding of this study was the neutral effect of
coffee consumption on the components of the lipid profile, as
reported by other authors (10, 38). The results of studies that
used unfiltered coffee have consistently shown the negative effect
of the beverage on plasma TC, an effect that has been attributed
to the diterpenes, specifically cafestol (39–41). Studies that
evaluated the effect of filtered coffee on lipids have reported
conflicting results; some studies have found the positive effects of
reduced TC and LDL cholesterol concentrations and increased
HDL cholesterol concentrations (42, 43). In contrast, other
studies have reported an increase of TC after coffee intake and a
decrease when coffee is not consumed (10, 38, 44). Naidoo et al.
(45) showed that the low content of cafestol in beverages
prepared with filters is not a risk for increased TC. Finally, the
results of two meta-analyses of the effect of coffee on blood
lipids attributed the negative effect to the diterpenes provided by
unfiltered coffee (7, 46).
The 400 mL of filtered coffee with medium and high CGA
content provided 0.89 mg and 0.92 mg of kahweol, respectively;
both provided 0.75 mg of cafestol. Among the volunteers of our
study, consumption of these beverages did not negatively affect
the lipid profile. In contrast with our results, in a crossover
clinical trial of healthy volunteers, Correˆa et al. (11) found an
increase in both TC as well as the HDL cholesterol concentra-
tion after the consumption for 4 wk of 482-mL light- or
medium-roasted filtered coffee/d containing antioxidants. Com-
pared with our study, the light- and medium-roasted coffee of
the Correˆa et al. study provided 21 and 25 times more cafestol,
respectively. Another important difference between our study
and that of Correˆa et al. was the intake of caffeine; in our
study the mean intake was 192mg/d, whereas in the Correˆa et al.
study it was 763 mg/d.
The effect of coffee on endothelial function has primarily
been evaluated acutely, and the effect of chronic coffee consump-
tion, to our knowledge, has been rarely studied. In our study, the
FMD values of the individuals who did not drink coffee did not
improve, and the FMD values of the individuals who drank
coffee showed no deterioration, contrary to previous reports
that evaluated the effect of acute coffee consumption on this
variable (12, 13). The authors attributed the unfavorable effect
on the endothelium to caffeine, which decreases the levels of
cyclic guanosine monophosphate, the second messenger of
L-arginine/NO (13). The positive or neutral effect of coffee on
the vascular endothelium could potentially be explained by the
action of CGAs, which may offset the possible negative effects of
caffeine (12). In our study, the total caffeine intake from the
2 types of coffee was considered safe (<300 mg/d) (47).
Various investigations have found that the consumption of
antioxidants, such as flavanols, may increase NO concentrations
(48); however, only a few studies, to our knowledge, have been
published regarding the effect of CGAs in coffee on NO
concentrations. In this study, the concentration of NO plasma
metabolites at 8 wk did not significantly differ between the
groups in terms of the effect over time or the treatment 3 time
interaction. Similar to these results, other authors have found no
differences in NO concentrations (15, 49).
In our study of normotensive habitual coffee drinkers, those
who drank coffee did not exhibit an increase in BP at 8 wk; in the
control group, BP also did not decrease. Consistent with these
results, a study of normotensive volunteers who drank between
200 and 600 mL of coffee for 6 wk did not report noteworthy
changes in BP (50). A possible explanation for these results is the
duration of consumption; the individuals who drank coffee over
this period may have developed a partial tolerance to caffeine, a
substance that is related to the increase in BP (49). Substances
in coffee, such as potassium, magnesium, and CGAs, have
been postulated to exert a protective effect on the vascular
system (51). More specifically, CGAs have been shown to
inhibit the activity of angiotensin-converting enzymes (49).
Finally, the relation between regular coffee consumption and
BP can be described as a J–shaped curve, where moderate
intake of this beverage may have a protective effect on BP,
whereas high coffee consumption could increase the risk of
hypertension (52).
Given the chemical complexity of coffee beverages, a limita-
tion of this study was that other CGA metabolites as well as
other components responsible for coffees total AC were not
measured. A strength of this study is that we used an amount of
coffee and method of preparation similar to those used by the
study population; thus, a recommendation to consume coffee in
accordance with the amounts and preparation method used in
this study is a feasible way to achieve the desirable antioxidant
effects without affecting the lipid profile or vascular function.
In conclusion, the results of this study demonstrated acute
absorption of the antioxidants in coffee after individuals con-
sumed coffee beverages with either a medium or high CGA
content. The results also revealed a positive acute effect on plasma
AC and that chronic consumption of 2 drinks with antiox-
idants, low diterpene concentrations, and a concentration of
caffeine within the recommended range had a neutral effect
on blood lipids and vascular function. Finally, it is important
to note that this study showed that ceasing to drink coffee did
not improve serum lipid profile, FMD, BP, or NO plasma
metabolites.
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